CochLear EBITDA 2023-2024 | CHEOY

CochLear EBITDA for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CochLear 2024 EBITDA was 0.367B, a 15.95% increase from 2023.
  • CochLear 2023 EBITDA was 0.317B, a 7.72% decline from 2022.
  • CochLear 2022 EBITDA was 0.343B, a 70.23% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

CochLear EBITDA 2023-2024 | CHEOY

  • CochLear 2024 EBITDA was 0.367B, a 15.95% increase from 2023.
  • CochLear 2023 EBITDA was 0.317B, a 7.72% decline from 2022.
  • CochLear 2022 EBITDA was 0.343B, a 70.23% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$143B
CVS Health (CVS)$82.3B
Elevance Health (ELV)$65.5B
Cencora (COR)$56.3B
DiDi Global (DIDIY)$25.6B
Labcorp Holdings (LH)$22.2B
Natera (NTRA)$21.6B
BioMerieux (BMXMF)$17.7B
EUROFINS SCIENT (ERFSF)$14.6B
ICON (ICLR)$12.9B
Medpace Holdings (MEDP)$12.6B
Solventum (SOLV)$12.5B
Viatris (VTRS)$11.5B
Revvity (RVTY)$10B
Sonic Healthcare (SKHHY)$9B
Avantor (AVTR)$8.2B
HealthEquity (HQY)$8B
Caris Life Sciences,�Inc (CAI)$7.7B
Charles River Laboratories (CRL)$7.3B
Bausch + Lomb (BLCO)$4.8B
Sotera Health (SHC)$4B
Amplifon S.p.A (AMFPF)$3.9B
BrightSpring Health Services (BTSG)$3.7B
GeneDx Holdings (WGS)$3.2B
Surgery Partners (SGRY)$2.9B
Alignment Healthcare (ALHC)$2.9B
Concentras Parent (CON)$2.8B
Organon (OGN)$2.3B
Premier (PINC)$1.9B
Progyny (PGNY)$1.9B